Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2019-09-10 AGM Information
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document explicitly discusses the results of the 'Combined General Meeting' held on September 5, 2019. It details the resolutions adopted by the shareholders, including the inclusion of the 'Raison d'être' in the articles of association and the approval/rejection of various mandates and compensation structures. This content is directly related to shareholder voting and meeting outcomes, which aligns perfectly with the definition of AGM Information (AGM-R). While it mentions the adoption of financial statements (which could relate to 10-K or IR), the primary focus and structure are centered around the meeting proceedings and voting results.
2019-09-10 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document is titled with a headline about the Annual General Meeting ('L'Assemblée Générale de MedinCell vote...'). The text explicitly mentions that shareholders met on September 5, 2019, in a 'Assemblée Générale Mixte' (Mixed General Meeting) and details the resolutions adopted, including the approval of accounts, renewal of board mandates, and changes to the company's statutes (raison d'être). This content is characteristic of materials presented or summarized following an Annual General Meeting (AGM). Although it lists adopted resolutions, it is a summary/report of the meeting's outcome, making 'AGM-R' (AGM Information) the most appropriate classification, rather than 'DVA' (Declaration of Voting Results), which is usually a more formal, standalone results announcement, or 'DEF 14A' (Remuneration Information), which is too specific. Given the context of the meeting and the summary of key decisions, AGM-R is the best fit.
2019-09-10 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated September 4, 2019, announcing that MedinCell has received a grant from the Bill & Melinda Gates Foundation to develop a long-acting injectable treatment for HIV prevention (PrEP). It details the scientific rationale, quotes the CEO, and provides company background and contact information. This type of announcement, focusing on a specific development, partnership, or funding event that is not a standard periodic financial report (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report, a management discussion, a dividend notice, or a specific capital change, the most appropriate classification is 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Capital/Financing Update' (CAP) due to the grant funding, but RNS is broader for press releases of this nature. Given the content is a news announcement about a development/grant, RNS is the best fit among the provided options for a non-standard, material press release.
2019-09-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is titled with a headline announcing a grant received by MedinCell for developing an HIV PrEP product. It includes a date (September 4, 2019), company boilerplate information, and contact details, formatted as a standard press release. This type of announcement, detailing a specific business development (grant funding, partnership, product progress) outside of routine financial reporting periods (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement. Since this is a specific, non-financial-result-focused announcement about a grant and development program, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material corporate event announcement that doesn't fit the more specific financial or governance codes. It is not a full report (10-K, IR), a transcript (CT), or a management discussion (MDA). Given the context of corporate news dissemination, RNS is the most appropriate fallback for significant, non-standard announcements.
2019-09-04 English
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is a press release dated August 28, 2019, announcing a partnership between MedinCell and Cornerstone Animal Health regarding the development of long-acting injectable veterinary products using MedinCell's BEPO® technology. This type of announcement, detailing a strategic business development, partnership, or significant operational update outside of routine financial reporting (like 10-K, ER, or IR), typically falls under general regulatory announcements or investor relations material. Since it is a formal press release announcing a significant business event (a partnership and development pipeline update) and does not fit the specific definitions for financial reports (10-K, IR, ER), capital changes (CAP, SHA), management changes (MANG), or voting results (DVA), the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal report (AR, IR). FY 2019
2019-08-28 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled with a date and time stamp (28 août 2019 17h45 (CEST)) and begins with a headline announcing a strategic partnership and development plan. It contains quotes from management and concludes with standard disclaimers typical of a press release regarding forward-looking statements and investment advice. This structure strongly indicates an official announcement of material news, which aligns best with an Earnings Release (ER) if it contained financial results, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement not covered by other specific codes. Since this is a strategic business development announcement (partnership, product pipeline updates) rather than a formal financial report (10-K, IR, ER), and it is presented as a 'communiqué de presse' (press release), the most appropriate general regulatory/corporate announcement category is RNS, as it is a material, non-financial-specific disclosure.
2019-08-28 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.